30.08.2023,
19052 Zeichen
London (ots/PRNewswire) - Next-generation laser vision correction
provides next-day results and recovery1,2
* The next-generation ELITATM Femtosecond Laser to correct myopia
with the new SILK procedure**
* The latest innovation in extended depth of focus (EDOF)
intraocular lenses (IOLs) will be shared with invited surgeons.
* Supporting ESCRS' Mission Zero target through ongoing
sustainability efforts
* More than 30 abstracts supported by Johnson and Johnson Vision to
be presented across a range of equipment and IOLs including:
TECNIS Synergy® IOL, TECNIS Eyhance® IOL and ELITA™ Femtosecond
Laser
* Participating in iNovation sessions on presbyopia, the
re-emergence of refractive surgery and myopia: the next pandemic
Johnson & Johnson Vision*, a global leader in eye health and part of
Johnson & Johnson MedTechi, will announce the launch of a
next-generation laser vision correction solution, the ELITATM
Platform, at the 41st European Society of Cataract and Refractive
Surgeons (ESCRS) congress, 8-12 September 2023. The congress will
also showcase a range of breakthrough data, with over 30 abstracts
supported by Johnson & Johnson Vision accepted for presentation.
The ELITATM Platform enables surgeons to perform refractive
correction on patients with myopia, with or without astigmatism,
using the new SILK (Smooth Incision Lenticule Keratomileusis)
procedure. With an ultra-precise laser pulse and fast laser delivery
system, the ELITATM Platform provides surgeons with a consistently
smooth and easy lenticular removal, offering exceptional vision
correction with next-day results and recovery.1,2,3
The SILK procedure helps correct myopia through an often quick and
minimally invasive process. The precise ELITATM Femtosecond Laser
uses fine laser pulses to gently create a small disc-shaped piece of
tissue called a lenticule in the cornea after the eye is numbed. The
lenticule is then delicately removed through a microscopic incision
and the smooth lenticule removal reshapes the cornea, correcting the
eye to see flawlessly.1,2
An integrated blend of sophisticated technologies enables surgeons to
perform the SILK procedure effortlessly and precisely to yield
next-day results for patients.1,2
* Ultra-Precise Pulse delivers better quality treatment of corneal
tissue1
* Ultra-Fast Delivery System enables contiguous placement of laser
pulses for exceptionally smooth tissue surface
* Sub-Micron Digital-Encoder Controlled Scanning System allows a
high-degree of pulse placement and superior optical performance
across the entire treatment area1
* Industry-first biconvex lenticule: Designed for better quality of
vision. Reduces cutting of corneal nerves and provides fast
regeneration for a healthy ocular surface
"We are delighted to launch our next-generation ELITATM Platform at
ESCRS this year as well as showcase our broad range of ophthalmic
innovations to our surgical customers", said Jacqueline Henderson,
President, EMEA, Johnson & Johnson Vision. "We have a rich heritage
of innovation at Johnson & Johnson Vision, and we're proud to offer
surgeons and their patients equipment and IOLs that serve the eye
health needs of patients across their lifetime".
The Johnson & Johnson Vision ESCRS Booth (#B202) will have live
demonstration areas for surgeons to experience first-hand the ELITATM
Femtosecond Laser as well as other leading Johnson & Johnson Vision
products. Additionally, attendees will be able to participate in the
Toric VR Simulator experience alongside dry labs and meet the expert
sessions at the booth and in the Johnson & Johnson Vision Lighthouse.
Key scientific abstracts supported by Johnson & Johnson Vision The
congress, taking place this year at the Messe Wien Exhibition &
Congress Centre in Vienna, will also see over 30 scientific
communications from both Johnson & Johnson Vision sponsored studies
and investigator-initiated studies (IIS) being presented, including:
ELITATM Femtosecond Laser
* Epithelial Corneal Nerves and Stromal Wound Healing Post
Lenticular Extraction Using New Femtosecond Laser
* Evaluation Ease of Lenticule Removal and Visual Outcomes After a
Lenticule Procedure with ELITATM Femtosecond Laser Platform
TECNIS Eyhance® Intraocular Lens
* Performance Comparative of Monofocal IOL with Enhanced Features
for Intermediate Vision to Current Standard Monofocal Lens
* A Scoping Review On The Placement Of Enhanced Monofocal Between
Conventional And Extended Depth Of Focus Intraocular Lenses
TECNIS Synergy® Intraocular Lens
* Safety And Efficacy Outcomes With A New
Continuous-Range-Of-Vision
Intraocular Lens
TECNIS Synergy® Toric II Intraocular Lens
* 6 Month Follow Up Comparison Of Rotational Stability Between
Zeiss
At Lisa 939 And Synergy Toric II For Correction Of Anisometropia
With Astigmatism And Presbyopia
* Refractive Results After Cataract Surgery And Implantation Of A
Trifocal Intraocular Lens– Model DFW-375 Tecnis Synergy Toric
TECNIS Symfony® and TECNIS Symfony® OptiBlue Intraocular Lenses
* Impact of Violet Light Filtration and High-Resolution Lathing on
the Clinical Performance of a Diffractive Extended Depth of Focus
IOL
A complete listing is available at:
https://congress.escrs.org/programme/online-programme/
Other representatives from Johnson & Johnson Vision will be
participating in events throughout ESCRS 23, including ESCRS
iNovation Day on the 8th at the Messe Wien Exhibition & Congress
Centre.
Jacqueline Henderson, President EMEA, Johnson & Johnson Vision will
be taking part in the European industry leadership roundtable on
visions for the next 5 years, Raj Rajpal, Chief Medical Officer,
Johnson & Johnson Vision will be joining the Managing presbyopia from
early stage to cataracts panel discussion, Xiao Yu Song, Global Head
of R&D, Johnson & Johnson Vision will discuss Myopia: The next
pandemic and Tobin Island, Senior Director, Laser and Software,
Johnson & Johnson Vision will be talking about the re-emergence of
refractive surgery: lenticule extraction and phakic IOLs.
Education and interactive sessions Johnson & Johnson Vision is also
hosting a series of educational and interactive sessions aimed at
sparking conversation and providing an opportunity to share, discuss
and learn from leading experts in the field of ophthalmology. These
include:
* EuroTimes Satellite Symposium – SILK: Re-Defining Technology
Innovation with the New Elite in Laser Refractive Surgery. Room
Strauss 3. 9th September, 13.00-14.00
* IME Symposia – Demystifying Common Misunderstandings with
Refractive IOL Procedures. Room A3. 9th September, 16.30-17.30
* IME Symposia – The Future of Refractive Surgery, Lenticle
Extraction, Phakic IOLs and Beyond. Room A3. 10th September 2023,
09.30-10.30
* EuroTimes Satellite Symposia – Regaining Pure Vision in
Intermediate Contrast. Room A4. 10th September, 13.00-14.00
Sustainability at ESCRS Following Johnson & Johnson Vision's
recognition at the 2022 ESCRS congress for its sustainability
efforts, it remains steadfast on tackling key issues that affect us
all, from recycling and reducing our carbon footprint, to limiting
our use of natural resources. This year the booth will include the
following elements:
* Up to 90% of the Booth will be made from recycled or recyclable
sources and materials and 90% of the Booth materials will be
reused after the congress
* Offsetting 100% of our CO2 emissions from the electricity used at
the Booth
* We are providing almost entirely locally sourced vegan food,
delivered to us from within a 30km radius of the congress centre
* Onsite recycling for anyone who has picked up paper elsewhere at
the congress, so they can dispose of it in a sustainable way.
* The booth will incorporate a digital tree auto calculating in
real
time the amount of CO2 saved on the booth
* Two bicycles on-site to provide a sustainable option for visitors
to recharge their digital devices
Driving diversity and inclusion To further build upon its commitment
to equality and inclusion, Johnson & Johnson Vision will also be
hosting the second Women in Ophthalmology networking and mentorship
event during ESCRS. A host of influential women who work in
ophthalmology, including Professor Beatrice Cochener, Professor Rita
Mencucci and Dr. Nancy Al Raqqad will meet for an engaging and
collaborative discussion on the power of success of women in
ophthalmology, bringing their own diverse viewpoints and personal
stories to help continue our mission to cultivate a productive and
inclusive environment in eye health.
For more information visit the Johnson & Johnson Vision booth #B202.
About Johnson & Johnson Vision* At Johnson & Johnson Vision*, part of
Johnson & Johnson MedTech**, as a global leader in eye health we have
a bold ambition: Vision Made Possible — paving the way for a new
future of eye health to support the full spectrum of pediatric, adult
and aging eyes. Through cutting-edge innovation, scientific
expertise, and advanced technologies, we are transforming the way
patients see and experience the world. At every step of the eye
health journey, we stand as a trusted partner, making dependable
outcomes possible for customers and patients. And, in communities
with greatest need, we work in collaboration to expand access to
quality eye care — for all. Visit us at jjvision.com, follow
@JNJVision on Twitter, Johnson & Johnson Vision on LinkedIn, and
@JNJVision on Facebook.
About Johnson & Johnson MedTechi At Johnson & Johnson MedTechi, we
unleash diverse healthcare expertise, purposeful technology, and a
passion for people to transform the future of medical intervention
and empower everyone to live their best life possible. For more than
a century, we have driven breakthrough scientific innovation to
address unmet needs and reimagine health. In surgery, orthopaedics,
vision, and interventional solutions, we continue to help save lives
and create a future where healthcare solutions are smarter, less
invasive, and more personalized.
About Myopia Myopia, also called nearsightedness, is a chronic and
progressive disease that poses the biggest eye health threat of the
21st century.4,5,6,7. Half of the world's population is projected to
be myopic by 2050, with nearly one billion people expected to have
high myopia8. Refractive surgery can correct myopia, allowing
patients to clearly see distant objects without glasses or contact
lenses.4
© Johnson & Johnson Surgical Vision, Inc. 2023. All rights reserved.
IMPORTANT SAFETY INFORMATION – Europe As with any medical procedure,
risks and potential complications may occur. Please consult your eye
care specialist for detailed information and to discuss these
possible risks and complications with you prior to the procedure.
INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR ELITA™ FEMTOSECOND
LASER
INDICATIONS FOR USE:
FLAP: The ELITATM Femtosecond Laser System is an ophthalmic
femtosecond laser indicated in the creation of a corneal flap in
patients undergoing LASIK surgery or other surgery or treatment
requiring initial lamellar resection of the cornea.
SILK: The ELITATM Femtosecond Laser System is indicated for corneal
refractive lenticule removal in the reduction or elimination of
myopia with and without astigmatism up to -12.00 D sphere, up to
-6.00 D cylinder, with the sum of sphere and cylinder between -1.00 D
and -12.00 D using minus cylinder convention.
The ELITATM System is used in conjunction with a sterile disposable
Patient Interface, consisting of a pre-sterilized suction ring
assembly and pre-sterilized applanation cone, intended for
single-use.
The ELITATM Patient Interface is designed for exclusive use with the
ELITATM System and indicated for corneal resection surgery. The
Patient Interface is intended for use on one eye and must not be
reused.
INTENDED USE/PURPOSE:
FLAP: The ELITATM Femtosecond Laser System is an ophthalmic
femtosecond laser intended to create a corneal flap in patients
undergoing LASIK surgery or other surgery treatment requiring initial
lamellar resection of the cornea. The ELITATM platform is used in
conjunction with a sterile disposable Patient Interface, consisting
of a pre-sterilized suction ring assembly and pre- sterilized
applanation cone, intended for single-use. The ELITATM Patient
Interface is designed for exclusive use with the ELITATM platform and
indicated for corneal resection surgery. The Patient Interface is
intended for use on one eye and must not be reused. The ELITATM
platform should only be operated by, or under the direct supervision
of a trained physician with certification in laser safety and in the
use of the ELITATM platform for corneal flaps.
SILK: The ELITATM Femtosecond Laser System is an ophthalmic
femtosecond laser intended for flapless refractive correction via
lenticule creation and removal, which alters the curvature of the
corneal surface so as to correct a patient's refraction. It is
indicated for the reduction or elimination of myopia with and without
astigmatism. The ELITATM Femtosecond Laser System is used in
conjunction with a sterile disposable Patient Interface, consisting
of a pre-sterilized suction ring assembly and pre-sterilized
applanation cone, intended for single-use. The ELITATM Patient
Interface is designed for exclusive use with the ELITATM System and
indicated for corneal resection surgery. The Patient Interface is
intended for use on one eye and must not be reused. The ELITATM
System should only be operated by, or under the direct supervision of
a trained physician with certification in laser safety and in the use
of the ELITATM System for Smooth Incision Lenticular Keratomileusis
(SILKTM) treatments.
CONTRAINDICATIONS:
FLAP: Lamellar resection for the creation of a corneal flap using the
ELITATM System is contraindicated if any of the following conditions
exist.
Contraindications include the following, but are not limited to:
* Corneal edema, Corneal lesions, Hypotony, Glaucoma, Keratoconus,
Existing corneal implant, Corneal Dystrophy, Unstable Refractive
error within the past year prior to treatment, Prior refractive
surgery.
SILK: Lamellar resection for the creation of a corneal lenticule
using the ELITA System is contraindicated if any of the following
conditions exist.
Contraindications include the following, but are not limited to:
* Corneal edema, Corneal lesions, Hypotony, Glaucoma, Keratoconus,
Existing corneal implant, Corneal Dystrophy, Unstable Refractive
error within the past year prior to treatment, Prior refractive
surgery.
UNDESIREABLE SIDE EFFECTS/ADVERSE EFFECTS:
FLAP: Undesirable Side Effects/Adverse Effects: Possible
complications resulting from this surgery include the following.
Potential complications are not limited to those included in this
list.
* Diffuse lamellar keratitis (DLK), Corneal edema, Corneal pain,
Epithelial ingrowth, Epithelial defect, Infection, Corneal
infiltrate/ulcer, Delayed healing, Corneal abrasion, Corneal
erosion, Corneal haze, Corneal scar, Corneal scoring,
Inhomogeneous stromal bed, Eye pain/excessive tearing/eye
redness,
Inflammation of the episcleral, Iritis/Uveitis, Unexpected loss
of
corneal tissue, Corneal ectasia, Elevated IOP, Hemorrhage,
Subconjunctival hemorrhage, Venous and arterial blockage, Retinal
vascular accidents, Ocular penetration, Cataract formation,
Dysphotopsia, Blurry vision or halo/starburst/glare around lights
at night, Ghost/ double images, Foreign body sensation or dry
eye,
Ptosis, Anesthesia/drug reactions, Transient light sensitivity
syndrome, Peripheral light spectrum/rainbow glare
SILK: Undesirable Side Effects/Adverse Effects: Possible
complications resulting from this surgery include the following.
Potential complications are not limited to those included in this
list.
* Diffuse lamellar keratitis (DLK), Corneal edema, Corneal pain,
Epithelial ingrowth, Epithelial defect, Infection, Corneal
infiltrate/ulcer, Delayed healing, Corneal abrasion, Corneal
erosion, Corneal haze, Corneal scar, Corneal scoring (Spoke-wheel
like or striae), Inhomogeneous stromal bed, Eye pain/excessive
tearing/eye redness, Inflammation of the episcleral,
Iritis/Uveitis, Unexpected loss of corneal tissue, Corneal
ectasia, Elevated IOP, Intraocular Hemorrhage, Subconjunctival
hemorrhage, Venous and arterial blockage, Retinal vascular
accidents, Ocular penetration, Cataract formation, Dysphotopsia,
Blurry vision or halo/starburst/glare around lights at night,
Ghost/ double images, Foreign body sensation or dry eye,
Anisometropia, Ptosis, Vision correction regression,
Anesthesia/drug reactions, De- centered lenticule, Incomplete
lenticule creation, Lenticule tearing or inability to remove
lenticule, Anterior corneal tear, Anterior corneal melt,
Lenticule
too deep or too shallow in the Cornea, Under or over refractive
correction, Induced higher order aberrations, Transient light
sensitivity syndrome, Peripheral light spectrum/rainbow glare
Vision Threatening Complications (these complications are uncommon,
but possible following refractive surgery):
* Perforation of the cornea, Retinal detachment, Partial or total
loss of vision or eye.
Intended Patient: Adults 18 years old or older with refractive error.
NOTE: Pregnant or nursing women were not included in the clinical
trials conducted.
1. DOF2023RF4002. ELITATM Femtosecond Laser Device Description
2. DOF2023RF4003. ELITA™ femtosecond laser SILK™ procedure long
term
safety and effectiveness – Subset of Phase 3 data (India sites
only)
3. ARVO 2023 LASIK Flap Accuracy Comparison Between A New
Femtosecond Laser and iFS, Mahipal Sachdev
4. Flitcroft DI et al. IMI–Defining and classifying myopia: a
proposed set of standards for clinical and epidemiologic studies.
Invest Ophthalmol Vis Sci. 2019;60:M20-30.
5. Donovan L, Sankaridurg P, Ho A et al. Myopia progression rates
in
urban children wearing single-vision spectacles. OVS
2012;89(1):27-32.
6. ** Pärssinen O, Kauppinen M. Risk factors for high myopia: a
22-year follow-up study from childhood to adulthood. Acta
Ophthalmologica. 2019;97(5):510-518.
7. ‡‡ Hu Y, Ding X, Guo X, Chen Y, Zhang J, He M. Association of
Age
at Myopia Onset with Risk of High Myopia in Adulthood in a
12-Year
Follow-up of a Chinese Cohort. Jama Ophthalmol.
2020;138(11):1129-1134. doi:10.1001/jamaophthalmol.2020.3451.
8. Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo K, et al. Global
Prevalence of Myopia and High Myopia and Temporal Trends from
2000
to 2050. Ophthalmol. 2016;123(5):1036-1042. doi:
10.1016/j.ophtha.2016.01.006.
0155-3005 Rev B_OUS EN FLAP
0155-3006 Rev B_OUS EN_SILK
SILK not yet approved for use in the U.S. This content is intended
for Healthcare Professionals only, not for the general public.
View original
content:https://www.prnewswire.co.uk/news-releases/johnson--johnson-v
ision-announces-launch-of-elita-platform-to-correct-myopia-with-new-s
ilk-procedure-at-the-european-society-of-cataract-and-refractive-surg
eons-congress-301912933.html
Digital press kit:
http://www.ots.at/pressemappe/PR132147/aom
BSN Podcasts
Christian Drastil: Wiener Börse Plausch
Wiener Börse Party #641: Guter Mai-Start, Commerzbank besiegt VIG knapp, RBI solide und Strabag-Blick heute Abend
Aktien auf dem Radar:Polytec Group, Immofinanz, Palfinger, Warimpex, Flughafen Wien, Austriacard Holdings AG, EVN, Rosgix, S Immo, Erste Group, Österreichische Post, Cleen Energy, Marinomed Biotech, Pierer Mobility, RBI, Addiko Bank, SW Umwelttechnik, Oberbank AG Stamm, Agrana, Amag, CA Immo, Kapsch TrafficCom, OMV, Telekom Austria, Uniqa, VIG, Wienerberger, Mercedes-Benz Group, Siemens Energy, Deutsche Post, Allianz.
KTM
Die KTM Industries-Gruppe ist eine europäische Fahrzeug-Gruppe mit dem strategischen Fokus auf das globale Sportmotorradsegment und den automotiven high-tech Komponentenbereich. Mit ihren weltweit bekannten Marken KTM, Husqvarna Motorcycles, WP und Pankl zählt sie in ihren Segmenten jeweils zu den Technologie- und Marktführern.
>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner
Mehr aktuelle OTS-Meldungen HIER